Biotechnology industry in India

Significant contributions to the BioEconomy and the global acceptance of biosimilar products are driving an expected growth to nearly US$ 63 billion by 2025, indicating a promising trajectory.

Advantage India

Skilled human
capital

*With a total population of 1.4 billion, 47% being under the age of 25, India has a large pool of young and skilled workforce.

*India has a large reservoir of scientific human resources including scientists and engineers.

*Biotechnology has emerged as a trending career option among the youth. According to a survey of Class 12th students in Delhi, Biotechnology was ranked as the preferred stream at No.4/5.

Infrastructure
facilities

* India currently has 12 DBT-supported biotechnology parks and 95 BIRAC-supported bio-incubators (75 Bio-NEST and 20 E-Yuva centres) as of 2025.

* Union Minister of Earth Sciences Dr. Jitendra Singh inaugurates the Northeast's first International Biotech Conclave.

* Department for Promotion of Industry and Internal Trade (DPIIT) signed an MoU with Thermo Fisher Scientific to support over 500 biotech startups in the next three years through advisory, technology access, mentorship, and investor connect.

Policy
Support

* The National Biopharma Mission (NBM–i3), led by DBT and implemented by BIRAC with World Bank support, has a Rs. 2,137 crore (US$ 250 million) budget, supports 101 projects with 150+ organisations and 30 MSMEs, set up 11 shared facilities, and created 1,000+ jobs including 304 scientists, alongside the Genome India Programme sequencing 10,000 genomes.

* The government envisions creating biofoundries, Bio AI centres, and thematic hubs focused on bio-based chemicals, smart proteins, and carbon capture as part of policy support to foster biomanufacturing and innovation.

* The Cabinet has approved the merger of two DBT schemes into ‘Biotechnology Research Innovation and Entrepreneurship Development (Bio-RIDE)’, with a new Biomanufacturing and Biofoundry component, allocating Rs. 9,197 crore (US$ 1.1 billion) for 2021-22 to 2025-26 under the 15th Finance Commission.

Epidemiological
factors

* Patient pool expected to increase over 20% in the next 10 years, mainly due to rise in population.

* New diseases & lifestyle changes to boost demand for drugs and devices.

Snapshot Showcase Infographics Reports

Last updated: May, 2026

Panacea Biotec

Panacea Biotec was established in 1984 under the name Panacea Drugs Private Limited and got publicly listed in September 1995. The company does research and development, manufacturing, sales, distribution and marketing of pharmaceuticals, vaccines and biosimilars. The company’s portfolio includes prescription products in niche therapeutic areas such as pain management, diabetes & cardiovascular management, oncology, renal disease management, osteoporosis management, anti-tubercular, gastro-intestinal care products and vaccines.

Company Website

SERUM INSTITUTE OF INDIA

Serum Institute of India Pvt. Ltd. manufactures several vaccines, which include Polio, Diphtheria, Tetanus, Pertussis, Hib, BCG, r-Hepatitis B, Measles, Mumps and Rubella vaccines. 65% of children in the world are estimated to receive at least one vaccine manufactured by Serum Institute. Vaccines manufactured by the Serum Institute are accredited by the World Health Organization.

Company Website

Biocon

Biocon is fully integrated, innovation-led biopharmaceutical company, focussed on delivering affordable innovation. The company delivers innovative biopharmaceutical solutions.

Company Website

Related News

12 May 26

Novartis Expands India Role in Global Drug Development...

Novartis is expanding India’s role in global drug development through increased focus on research, clinical operations, AI-enabled innovation and advanced pharmaceutical capabilities.

27 Apr 26

India’s bio-economy projected to reach US$ 1 trillion by 2047: MoS Dr. Jitendra Singh...

India’s bio-economy is set to reach Rs. 92.44 lakh crore (US$ 1 trillion) by 2047, driven by rapid biotech growth and policy support.

17 Apr 26

India, Austria to deepen ties in Defence, Technology: Prime Minister Mr. Narendra Modi...

India and Austria have elevated their bilateral ties with a strong focus on defence, advanced technologies and innovation-led collaboration, marking a new era in strategic and economic partnership.

15 Apr 26

India Pharma 2026 concludes with a strong push for enhanced funding, infrastructure and speed to accelerate pharmaceutical innovation...

India Pharma 2026 concluded with a strong call for enhanced funding, infrastructure and faster execution to drive innovation-led growth in pharmaceuticals, advanced therapeutics and biopharma.

13 Apr 26

India Pharma 2026 Commences in New Delhi, Showcasing India’s Innovation-Led Pharma Growth...

India Pharma 2026 will bring together policymakers and global pharma leaders in New Delhi to accelerate innovation-led growth, resilient supply chains, and India’s transition into a global life-sciences hub.